Upcoming event
23rd Meeting of the EAU Robotic Urology Section
Back

Tags

Article of the Month, Artificial intelligence, ASCO GU22, ASCO21, AUA21, Cabozantinib, Carcinoma, Chronic kidney disease, Cryosurgery, cystic masses, EAU, EAU21, EAU22, EMUC21, EMUC22, ERUS22, ESMO21, ESMO25, expert interview, Frail patient​, Glomerular filtration rate, Guidelines, IMDC risk model, Kidney cancer, Laparoscopy, localised renal cell carcinoma, Lymph node metastases, Lymph nodes, Metastasectomy, Mortality, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, Overall survival, Partial nephrectomy, Prognostication, Radical nephrectomy, Radical surgery, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, Robotic, Robotic prostatectomy, Robotic surgery, stereotactic body radiation therapy, Survival outcome, Suture, Targeted therapies, Treatment response, Urological surgery, UROonco24, UROonco25, UROwebinar, Webinar
Show all

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)

View

Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC)

View

The serum level of the components of the renin-angiotensin system correlates with its tumor tissue expression in kidney cancer patients

View

Intrarenal renin-angiotensin system in hypertensive patients with localized kidney cancer

View

Cost-effectiveness of first-line therapy for advanced renal cell carcinoma in the immunotherapy era

View

Clinical outcomes of checkpoint inhibitors in metastatic non-clear cell renal cell carcinoma and clear cell renal cell carcinoma with variant features

View

Hypertension and cardiovascular morbidity following surgery for kidney cancer

European Urology Oncology, Volume 3, Issue 2, April 2020, Pages 209-215

View

Topographic distribution of first landing sites of lymphatic metastases from patients with renal cancer

Urologic Oncology: Seminars and Original Investigations, Volume 38, Issue 5, May 2020, Pages 521-525

View

Local recurrence following resection of intermediate-high risk nonmetastatic renal cell carcinoma: an anatomical classification and analysis of the ASSURE (ECOG-ACRIN E2805) adjuvant trial

Journal of Urology, October 2020

View

First-line immuno-oncology combination therapies in metastatic renal-cell carcinoma: results from the international metastatic renal-cell carcinoma database consortium

European Urology, Volume 76, Issue 6, December 2020, Pages 861-867

View

Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC)

View

Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study

View
PreviousNext